Fig. 2
From: Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system
The anti-migraine effect of the CGRP receptor antagonists MK-0974 and olcegepant and the triptans rizatriptan and sumatriptan compared to placebo at 2-h pain relief. The overall treatment effect of MK-0974 (p = 0.015) and rizatriptan (p = 0.010) showed significance versus placebo (left part) [69]. A dose of 2.5 mg of olcegepant also showed significant superiority over placebo (p = 0.001) [41]. Data of sumatriptan from another study [42] were added to demonstrate the similar efficacy of olcegepant compared to triptans